Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy

Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (irAEs) continues to rise, and rare toxicity continu...

Descripción completa

Detalles Bibliográficos
Autores principales: Falade, Ayo S., Reynolds, Kerry L., Zubiri, Leyre, Deshpande, Vikram, Fintelmann, Florian J., Dougan, Michael, Mooradian, Meghan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049212/
https://www.ncbi.nlm.nih.gov/pubmed/35493494
http://dx.doi.org/10.3389/fimmu.2022.871452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049212/
https://www.ncbi.nlm.nih.gov/pubmed/35493494
http://dx.doi.org/10.3389/fimmu.2022.871452

Ejemplares similares